Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with interleukin-2 in treating patients with metastatic melanoma.

Key facts

Study ID

NCT00003568

Run by

University of Illinois at Chicago

Starts

1998-11-01

Expected to finish

2005-12-01

Last updated by the study team

2013-06-26

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• University of Illinois at Chicago Health Sciences Center — Chicago, Illinois, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Comprehensive Cancer Center at Our Lady of Mercy Medical CenterOur — The Bronx, New York, United States
• University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.